BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

Bristol Myers BMY has a broad oncology portfolio, which includes blockbuster immuno-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others. Among these, Opdivo (nivolumab) is the top revenue ...

Poor commercial real estate. Fewer investors want to touch it after being burned by falling property values in recent years. They have better options anyway. Why settle for 7% annual returns on real ...

Bristol Myers Squibb BMY and Gilead Sciences, Inc. GILD are leading biotechnology companies with broad, diverse portfolios and a global footprint. BMY boasts a strong portfolio with drugs for oncology ...

Following a middling phase 3 readout for gastric cancer candidate bemarituzumab, Amgen has now stopped another phase 1b/3 trial of the molecule, the pharma announced in its third-quarter earnings Nov.

(Reuters) -Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a ...

Oct 1 (Reuters) - Microsoft (MSFT.O), opens new tab Chief Commercial Officer Judson Althoff will take on an expanded role as CEO of commercial business, freeing up company chief Satya Nadella to focus ...

Forbes contributors publish independent expert analyses and insights. I’m an investment sales broker and real estate investor based in NYC. As you consider investing in commercial real estate, you may ...

In 1969, a now-iconic commercial first popped the question, “How many licks does it take to get to the Tootsie Roll center of a Tootsie Pop?” This deceptively simple line in a 30-second script managed ...